Yıl: 2020 Cilt: 3 Sayı: 1 Sayfa Aralığı: 8 - 13 Metin Dili: İngilizce DOI: 10.14744/ijmb.2019.49469 İndeks Tarihi: 24-09-2020

The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease

Öz:
Objectives: There is growing evidence that oxidative modification of low-density lipoprotein (LDL) plays a central rolein the pathogenesis of atherosclerosis, which is increasingly seen at younger ages, and that high-density lipoprotein(HDL) levels are inversely associated with the risk of coronary artery disease (CAD). Cholesteryl ester transfer protein(CETP) has a role in the regulation of plasma HDL levels. The most studied polymorphism in the CETP gene is the Taq1Bpolymorphism, which has consistently been correlated with HDL levels. This case control study of a young (<50 years)Turkish population group with CAD was designed to assess whether there is a relationship between LDL oxidation andCETP Taq1B polymorphism.Methods: A total of 97 patients with CAD and 43 healthy volunteers were included in the study. Traditional risk factorsfor CAD (age, gender, smoking, hypertension) were evaluated in the patient group. Oxidative markers of LDL were determinedin both groups, as well as routine biochemical parameters. Following DNA extraction from white cells, CETPTaq1B polymorphism was determined using polymerase chain reaction amplification and restriction enzyme digestion.Fragments 174 and 361bp were identified as B1, and unrestricted 535 bp fragments as B2.Results: There was no statistical significance between the B1B1, B1B2, B2B2 genotypes in the patient group in terms ofbody mass index, waist-to-hip ratio, or biochemical parameters. Though the HDL cholesterol levels were higher in theB2B2 genotype, there was no statistically significant difference in comparison with the control group.Conclusion: The genetic polymorphism of CETP had no significant effect on CETP function and the CETP polymorphismshould not be proposed as an independent risk factor for cardiovascular events.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. https://www.who.int/news-room/fact-sheets/detail/the-top- 10-causes-of-death. Accessed Oct 2019.
  • 2. Chisolm Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000;28:1815–26.
  • 3. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160–7.
  • 4. Inazu A, Koizumi J, Mabuchi H. Cholesteryl ester transfer protein and atherosclerosis. Curr Opin Lipidol 2000;11:389–96.
  • 5. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967–74.
  • 6. Marotti Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364:73–5.
  • 7. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999;19:1105–10.
  • 8. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995;96:2071–4.
  • 9. Kako Y, Massé M, Huang LS, Tall AR, Goldberg IJ. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J Lipid Res 2002;43:872–7.
  • 10. Bérard AM, Föger B, Remaley A, Shamburek R, Vaisman BL, Talley G, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997;3:744–9.
  • 11. Goto A, Sasai K, Suzuki S, Fukutomi T, Ito S, Matsushita T, et al. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. Atherosclerosis 2001;159:153–63.
  • 12. Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005;111:1847–54.
  • 13. Freeman DJ, Griffin BA, Holmes AP, Lindsay GM, Gaffney D, Packard CJ, et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994;14:336–44.
  • 14. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000;20:1323–9.
  • 15. Kuivenhoven JA, de Knijff P, Boer JM, Smalheer HA, Botma GJ, Seidell JC, et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997;17:560–8.
  • 16. Kaman D, İlhan N, İlhan N, Akbulut M. TaqIB and severity of coronary artery disease in the Turkish population: a pilot study. Bosn J Basic Med Sci 2015;15:9–13.
  • 17. Geldmacher-v Mallinckrodt M, Hommel G, Dumbach J. On the genetics of the human serum paraoxonase (EC 3.1.1.2). Hum Genet 1979;50:313–26.
  • 18. Taus M, Ferretti G, Dousset N, Moreau J, Battino M, Solera ML, et al. Susceptibility to in vitro lipid peroxidation of low density lipoproteins and erythrocyte membranes from liver cirrhotic patients. Scand J Clin Lab Invest 1994;54:147–53.
  • 19. Sözmen EY, Sözmen B, Girgin FK, Delen Y, Azarsiz E, Erdener D, et al. Antioxidant enzymes and paraoxonase show a co-activity in preserving low-density lipoprotein from oxidation. Clin Exp Med 2001;1:195–9.
  • 20. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004;109:III15–9.
  • 21. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 1992;339:1183–6.
  • 22. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G, et al. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001;22:2075–84.
  • 23. Durrington PN, Mackness B, and Mackness MI. 9. Role of HDL in preventing atherogenic modification of LDL. Atherosclerosis 1999;146:S13.
  • 24. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274–83.
  • 25. Mirhafez SR, Avan A, Khatamianfar S, Ghasemi F, Moohebati M, Ebrahimi M, et al. There is an association between a genetic polymorphism in the ZNF259 gene involved in lipid metabolism and coronary artery disease. Gene 2019;704:80–5.
  • 26. Tanrikulu-Kucuk S, Ademoglu E, Gurdol F, Bilge AK, Mutlu- Turkoglu U, Nisanci Y. Cholesteryl ester transfer protein Taq1B polymorphism in an angiographically assessed Turkish population: no effects on coronary artery disease risk. Genet Test Mol Biomarkers. 2010;14:637–42.
  • 27. Yilmaz H, Isbir T, Agachan B, Karaali ZE. Effects of cholesterol ester transfer protein Taq1B gene polymorphism on serum lipoprotein levels in Turkish coronary artery disease patients. Cell Biochem Funct 2005;23:23–8.
  • 28. Ozsait B, Kömürcü Bayrak E, Poda M, Can G, Hergenç G, Onat A, et al. CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome. Anadolu Kardiyol Derg 2008;8:324–30.
  • 29. Arca M, Montali A, Ombres D, Battiloro E, Campagna F, Ricci G, et al. Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis. Clin Genet 2001;60:374–80.
  • 30. Lu Y, Tayebi N, Li H, Saha N, Yang H, Heng CK. Association of CETP Taq1B and -629C>A polymorphisms with coronary artery disease and lipid levels in the multi-ethnic Singaporean population. Lipids Health Dis 2013;12:85.
  • 31. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86–93.
  • 32. Delattre J, Therond P, Vasson MP, Legrand A, and Rousselett DB. Deleterious vascular effects of oxidized LDL and their modulation by antioxidants. In 20th Espen congress. 1998. Nice, France.
  • 33. Eiriksdottir Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V. The− 629C> A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis 2001;159:187–92.
  • 34. Yu DD, Ren QQ, Dong B, Zhao DD, Sun YH. Effect of Cholesteryl Ester Transfer Protein Gene TaqIB Polymorphism on the Risk of Ischemic Stroke: A Meta-Analysis. J Stroke Cerebrovasc Dis 2017;26:2354–61.
  • 35. Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HO, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J 2003;146:1007–14.
APA ilanbey B, Kayikcioglu M, Demirel Sezer E, pehlivan s, Girgin Sagin F, Ozkinay F, Y. Sozmen E (2020). The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. , 8 - 13. 10.14744/ijmb.2019.49469
Chicago ilanbey Bilal,Kayikcioglu Meral,Demirel Sezer Ebru,pehlivan sacide,Girgin Sagin Ferhan,Ozkinay Ferda,Y. Sozmen Eser The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. (2020): 8 - 13. 10.14744/ijmb.2019.49469
MLA ilanbey Bilal,Kayikcioglu Meral,Demirel Sezer Ebru,pehlivan sacide,Girgin Sagin Ferhan,Ozkinay Ferda,Y. Sozmen Eser The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. , 2020, ss.8 - 13. 10.14744/ijmb.2019.49469
AMA ilanbey B,Kayikcioglu M,Demirel Sezer E,pehlivan s,Girgin Sagin F,Ozkinay F,Y. Sozmen E The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. . 2020; 8 - 13. 10.14744/ijmb.2019.49469
Vancouver ilanbey B,Kayikcioglu M,Demirel Sezer E,pehlivan s,Girgin Sagin F,Ozkinay F,Y. Sozmen E The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. . 2020; 8 - 13. 10.14744/ijmb.2019.49469
IEEE ilanbey B,Kayikcioglu M,Demirel Sezer E,pehlivan s,Girgin Sagin F,Ozkinay F,Y. Sozmen E "The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease." , ss.8 - 13, 2020. 10.14744/ijmb.2019.49469
ISNAD ilanbey, Bilal vd. "The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease". (2020), 8-13. https://doi.org/10.14744/ijmb.2019.49469
APA ilanbey B, Kayikcioglu M, Demirel Sezer E, pehlivan s, Girgin Sagin F, Ozkinay F, Y. Sozmen E (2020). The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. International Journal of Medical Biochemistry, 3(1), 8 - 13. 10.14744/ijmb.2019.49469
Chicago ilanbey Bilal,Kayikcioglu Meral,Demirel Sezer Ebru,pehlivan sacide,Girgin Sagin Ferhan,Ozkinay Ferda,Y. Sozmen Eser The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. International Journal of Medical Biochemistry 3, no.1 (2020): 8 - 13. 10.14744/ijmb.2019.49469
MLA ilanbey Bilal,Kayikcioglu Meral,Demirel Sezer Ebru,pehlivan sacide,Girgin Sagin Ferhan,Ozkinay Ferda,Y. Sozmen Eser The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. International Journal of Medical Biochemistry, vol.3, no.1, 2020, ss.8 - 13. 10.14744/ijmb.2019.49469
AMA ilanbey B,Kayikcioglu M,Demirel Sezer E,pehlivan s,Girgin Sagin F,Ozkinay F,Y. Sozmen E The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. International Journal of Medical Biochemistry. 2020; 3(1): 8 - 13. 10.14744/ijmb.2019.49469
Vancouver ilanbey B,Kayikcioglu M,Demirel Sezer E,pehlivan s,Girgin Sagin F,Ozkinay F,Y. Sozmen E The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease. International Journal of Medical Biochemistry. 2020; 3(1): 8 - 13. 10.14744/ijmb.2019.49469
IEEE ilanbey B,Kayikcioglu M,Demirel Sezer E,pehlivan s,Girgin Sagin F,Ozkinay F,Y. Sozmen E "The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease." International Journal of Medical Biochemistry, 3, ss.8 - 13, 2020. 10.14744/ijmb.2019.49469
ISNAD ilanbey, Bilal vd. "The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease". International Journal of Medical Biochemistry 3/1 (2020), 8-13. https://doi.org/10.14744/ijmb.2019.49469